Hospital
Aspirus Rhinelander & Tomahawk Hospitals & Clinics, INC.
Aspirus Rhinelander & Tomahawk Hospitals & Clinics, INC. was paid $3.60M by Medicaid between Jan 2018 and Dec 2024, across 61 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoASPIRUS RHINELANDER & TOMAHAWK HOSPITALS & CLINICS, INC.
TOMAHAWK, WI 54487
TOMAHAWK, WI 54487
33aNPI1598715401assigned 05/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.60M
24GClaims58,373
24DCodes billed61
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#30 of 60
Median peer was paid$2.90M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,522 | $559K | |
| 2019 | 10,643 | $558K | |
| 2020 | 7,284 | $415K | |
| 2021 | 7,879 | $463K | |
| 2022 | 7,662 | $533K | |
| 2023 | 8,316 | $669K | |
| 2024incomplete | 6,067 | $406K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 4,525 | 3,698 | $1.01M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 2,670 | 2,173 | $669K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 2,016 | 1,625 | $494K |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 893 | 632 | $479K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.8% | 1,680 | 1,324 | $354K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.8% | 3,189 | 2,682 | $102K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 165 | 142 | $56K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 183 | 175 | $39K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.0% | 1,596 | 1,428 | $37K |
| 80053 | Comprehensive metabolic panel | <1% | 4,656 | 3,695 | $34K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,870 | 1,259 | $32K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 279 | 255 | $32K |
49 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 344 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,742 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 958 | $23K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 61 | $20K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,468 | $19K |
| 80061 | Lipid panel | <1% | 1,618 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 72 | $17K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,613 | $17K |
| 99001 | <1% | 1,855 | $11K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 830 | $10K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 288 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,168 | $8K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 91 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 47 | $7K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 339 | $5K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 407 | $5K |
| 81001 | <1% | 1,952 | $4K | |
| 84484 | <1% | 758 | $4K | |
| 83735 | <1% | 669 | $2K | |
| 85610 | <1% | 692 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,281 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 30 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,666 | $1K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 159 | $759.89 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 141 | $668.92 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 17 | $575.55 |
| 90686 | <1% | 57 | $463.74 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 987 | $410.59 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $402.77 |
| 81003 | <1% | 251 | $396.28 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 303 | $350.20 |
| 85027 | <1% | 70 | $277.56 | |
| 83690 | <1% | 67 | $267.94 | |
| 83605 | <1% | 54 | $203.10 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 14 | $164.24 |
| 71045 | Radiologic examination, chest; single view | <1% | 130 | $163.85 |
| 84439 | <1% | 16 | $133.86 | |
| 81025 | <1% | 21 | $85.70 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 718 | $50.92 |
| 85730 | <1% | 12 | $37.75 | |
| 87088 | <1% | 12 | $33.44 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 676 | $26.49 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 195 | $5.00 |
| 90674 | <1% | 34 | $0.49 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 341 | $0.11 |
| A9270 | Non-covered item or service | 0% | 202 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 55 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 142 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.